• Omeprazole (A2845): Technical Guidance for Gastric Acid Rese

  2026-04-22

  Omeprazole (SKU A2845) is a potent H+,K+-ATPase inhibitor optimized for gastric acid secretion and antiulcer research. It addresses the need for reproducible inhibition of gastric proton pumps in mechanistic and translational workflows. This reagent should not be used for diagnostic or therapeutic purposes outside controlled research settings.

• Rapid Protein Visualization with InstaBlue Protein Stain Sol

  2026-04-22

  InstaBlue Protein Stain Solution redefines protein electrophoresis analysis, delivering sensitive, ultra-fast, and mass spectrometry-compatible staining in minutes. Its unique formulation and workflow enhancements make it indispensable for biomedical research where clarity, speed, and data integrity are non-negotiable.

• Harnessing CA-074: Cathepsin B Inhibition for Disease Pathwa

  2026-04-21

  Explore how the cathepsin B inhibitor CA-074 enables high-precision dissection of necroptosis, cancer metastasis, and immune modulation pathways. This article delivers advanced assay guidance and unique reference integration for researchers using CA-074.

• Nitrocefin in β-Lactamase Evolution: From Resistance Mapping

  2026-04-21

  Explore how Nitrocefin, a chromogenic cephalosporin substrate, advances β-lactam antibiotic resistance research by enabling mechanistic dissection of complex β-lactamase activity, with unique focus on evolving enzymes like GOB-38. Gain practical and strategic insights beyond standard colorimetric assays.

• G-1 (CAS 881639-98-1): Precision GPR30 Agonist for Immune Mo

  2026-04-20

  Explore how G-1, a selective GPR30 agonist, enables rigorously targeted modulation of immune function and cardiovascular outcomes—bridging molecular signaling to translational research. This article uniquely dissects assay-critical insights and practical protocols for advanced experimental design.

• 5-hme-dCTP in Epigenetic DNA Hydroxymethylation Assays

  2026-04-20

  5-hme-dCTP unlocks robust single-base resolution for plant epigenetic research, enabling precise mapping of 5-hydroxymethylcytosine dynamics during stress adaptation. Discover how APExBIO's high-purity nucleotide empowers advanced workflows and troubleshooting in DNA hydroxymethylation assays.

• Entecavir (BMS200475): Resistance Landscape and Clinical Imp

  2026-04-19

  Explore the evolving landscape of Entecavir resistance in chronic hepatitis B therapy. This in-depth review uniquely analyzes meta-analytic evidence, assay parameters, and clinical implications for advanced HBV research and treatment.

• SM-164: Bivalent Smac Mimetic for Advanced Apoptosis Assays

  2026-04-18

  SM-164, a potent bivalent Smac mimetic, empowers researchers to dissect and induce TNFα-dependent apoptosis with high specificity in resistant cancer models. This article delivers actionable workflows, advanced troubleshooting, and evidence-backed protocol parameters, setting a new standard for apoptosis induction in tumor cell studies.

• ATRX-Deficient Glioma Sensitivity to RTK Inhibitors: Study I

  2026-04-17

  This study identifies that high-grade glioma cells with ATRX deficiency exhibit significantly increased sensitivity to multi-targeted receptor tyrosine kinase (RTK) and PDGFR inhibitors. The findings highlight the potential for stratified therapeutic strategies based on ATRX status, urging its consideration in future clinical trial designs.

• XAV-939: Precision Wnt/β-Catenin Modulation in Fibrosis & Bo

  2026-04-16

  XAV-939 (NVP-XAV939) stands out as a potent, selective tankyrase inhibitor, empowering researchers to dissect Wnt/β-catenin signaling in cancer, fibrosis, and bone biology. This guide translates recent scalable regenerative workflows and troubleshooting insights into protocol-ready strategies for superior experimental outcomes.

• Dovitinib (TKI-258): Precision RTK Inhibition in Cancer Mode

  2026-04-15

  Dovitinib (TKI-258, CHIR-258) is a multitargeted RTK inhibitor that enables robust, apoptosis-focused cancer research through precise ERK/STAT pathway suppression. This guide reveals advanced workflows, troubleshooting strategies, and actionable insights for maximizing Dovitinib’s translational impact in oncology studies.

• Sunitinib: Precision Multi-Targeted RTK Inhibitor Workflows

  2026-04-14

  Sunitinib from APExBIO delivers reproducible, high-sensitivity inhibition of multiple receptor tyrosine kinases, enabling advanced cancer research into angiogenesis, cell cycle arrest, and apoptosis. This article translates cutting-edge evidence—such as ATRX-deficiency sensitization in glioma—into optimized protocols, troubleshooting guides, and comparative insights for reliable experimental outcomes.

• Myriocin Restores Metabolic Balance in dAGE-Induced Obesity

  2026-04-13

  This study demonstrates that Myriocin, a selective serine palmitoyltransferase inhibitor, can reverse metabolic dysfunction in mice exposed to high dietary advanced glycation end products (dAGEs). By activating AMPK-PGC1α signaling and enhancing mitochondrial function, Myriocin offers a novel, evidence-based strategy for combating obesity and metabolic syndrome.

• Evaluating In Vitro Drug Responses: Insights from Fractional

  2026-04-13

  Schwartz's dissertation advances in vitro oncology research by dissecting the distinct contributions of proliferative arrest and cell death in anti-cancer drug evaluation. This work refines our understanding of drug action metrics, supporting more reproducible and interpretable preclinical assay design.

• EDI3 Inhibition Reduces Growth in HER2-Resistant Breast Canc

  2026-04-12

  Keller et al. (2023) identify EDI3 as a critical metabolic enzyme highly expressed in ER-HER2+ breast cancer cells that are resistant to HER2-targeted therapy. Inhibiting EDI3 reduces cell viability and tumor growth, highlighting a promising metabolic target in treatment-refractory breast cancer.

15138 records 3/1010 page Previous Next 12345 下5页 Last page